Table 1.
Patient characteristics (n = 20)
| Variable | |
|---|---|
| Age (years, mean ± SD) | 72.1 ± 8.6 |
| Gleason score (mean ± SD) | 9 ± 1 |
| Previous treatments (%) | |
| Radical prostatectomy | 45 |
| Primary radiation therapy | 15 |
| Salvage radiation therapy | 65 |
| Androgen deprivation therapy | 100 |
| Enzalutamide | 75 |
| Abiraterone acetate | 90 |
| Previous chemotherapy | 95 |
| Docetaxel | 95 |
| Cabazitaxel | 50 |
| Laboratory values at baseline (mean ± SD) | |
| AST (U/I) | 59 ± 84 |
| ALT (U/I) | 21 ± 12 |
| AP (U/I) | 241 ± 194 |
| LDH (U/I) | 515 ± 420 |
| PSA (μg/L) | 309.8 ± 418.3 |
| Site of tumor lesions (%) | |
| Skeleton | 100 |
| Lymph nodes | 90 |
| Liver | 10 |
| Prostate/Prostate bed | 55 |
| PET-based parameters at baseline (mean ± SD) | |
| SUVmax | 19.4 ± 11.4 |
| SUVmean | 12.6 ± 8.2 |
| PSMA-TV (cm3) | 226.5 ± 195.8 |
ALT, alanine transaminase; AP, alkaline phosphatase; AST, aspartate transaminase; LDH, lactate dehydrogenase; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RLT, Radioligand therapy; SUV, standardized uptake value; TV, tumor volume